New stroke drug tested in routine care: could it be safer?
NCT ID NCT05697575
First seen Apr 25, 2026 · Last updated May 20, 2026 · Updated 5 times
Summary
This study looks at how well a new clot-busting drug, non-immune staphylokinase, works for people having a stroke. Researchers will compare it to the standard drug alteplase by tracking bleeding risks and other outcomes in about 336 patients aged 18 to 85. The goal is to see if the new drug is as effective and safe in everyday hospital settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze
RECRUITINGSaint Petersburg, Russia
Contact
Conditions
Explore the condition pages connected to this study.